Vangelista

Protein engineering and therapeutics

Luca Vangelista, Group Leader

vangelista.luca@hsr.it


Our group focuses mostly on the production of HIV-1 entry inhibitors based on derivatives of CCL5/RANTES (full-length mutants and short peptides) for their development as mucosal microbicides targeting CCR5. Moreover, our potent CCL5 mutants will be tested on pathologies, aside AIDS/HIV, where CCL5 is of major relevance (e.g., inflammation and cancer). We are also implementing commensal bacteria engineering to combat various worldwide pathological threats (including HIV-1, allergy and avian influenza). On a different research area, we are investigating the role of IgE as antitumor agent, making use of a unique collection of mice engineered in relation to the IgE system.